Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors

References

• Altamura AC, Cavallaro R, Regazzetti MG. 1990. Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics. Eur Arch Psychiatry Clin Neurosci. 240:9–12.
   PubMed Web of Science ®Google Scholar
• Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. 2010. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry. 67:255–262.
   PubMed Web of Science ®Google Scholar
• Bolden C, Cusack B, Richelson E. 1992. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther. 260:576–580.
   PubMed Web of Science ®Google Scholar
• Campbell N, Boustani M, Limbil T, Ott C, Fox C, Maidment I, Schubert CC, Munger S, Fick D, Miller D, et al. 2009. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 4:225–233.
   PubMed Web of Science ®Google Scholar
• Churchill GA, Doerge RW. 2011. Empirical threshold values for quantitative trait mapping. Genetics. 138:963–971.
   Google Scholar
• Cohen-Woods S, Gaysina D, Craddock N, Farmer A, Gray J, Gunasinghe C, Hoda F, Jones L, Knight J, Korszun A, et al. 2009. Depression Case Control (DeCC) Study fails to support involvement of the muscarinic acetylcholine receptor M2 (CHRM2) gene in recurrent major depressive disorder. Hum Mol Genet. 18:1504–1509.
   PubMed Web of Science ®Google Scholar
• Deffains M, Bergman H. 2015. Striatal cholinergic interneurons and cortico-striatal synaptic plasticity in health and disease. Mov Disord. 30:1014–1025.
   PubMed Web of Science ®Google Scholar
• Desmarais JE, Beauclair L, Margolese HC. 2012. Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol (Oxford). 26:1167–1174.
   PubMed Web of Science ®Google Scholar
• Drevets WC, Zarate CA, Jr, Furey ML. 2013. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry. 273:1156–1163.
   Google Scholar
• Goldberg JA, Ding JB, Surmeier DJ. 2012. Muscarinic modulation of striatal function and circuitry. Handb Exp Pharmacol. 208:223–241.
   Google Scholar
• Gonzales KK, Smith Y. 2015. Cholinergic interneurons in the dorsal and ventral striatum: anatomical and functional considerations in normal and diseased conditions. Ann N Y Acad Sci. 1349:1–45.
   PubMed Web of Science ®Google Scholar
• Hshieh TT, Fong TG, Marcantonio ER, Inouye SK. 2008. Cholinergic deficiency hypothesis in delirium: a synthesis of current evidence. J Gerontol A Biol Sci Med Sci. 63:764–772.
   PubMed Web of Science ®Google Scholar
• Jagannathan K, Calhoun VD, Gelernter J, Stevens MC, Liu J, Bolognani F, Windemuth A, Ruaño G, Assaf M, Pearlson GD, et al. 2010. Genetic associations of brain structural networks in schizophrenia: a preliminary study. Biol Psychiatry. 68:657–666.
   PubMed Web of Science ®Google Scholar
• Jankelowitz SK. 2013. Treatment of neurolept-induced tardive dyskinesia. Neuropsychiatr Dis Treat. 9:1371–1380.
   PubMed Web of Science ®Google Scholar
• Jeon WJ, Dean B, Scarr E, Gibbons A. 2015. The role of muscarinic receptors in the pathophysiology of mood disorders: a potential novel treatment? Curr Neuropharmacol. 13:739–749.
   PubMed Web of Science ®Google Scholar
• Jiang S, Li Y, Zhang C, Zhao Y, Bu G, Xu H, Zhang Y-W. 2014. M1 muscarinic acetylcholine receptor in Alzheimer's disease. Neurosci Bull. 30:295–307.
   PubMed Web of Science ®Google Scholar
• Liao D-L, Hong C-J, Chen H-M, Chen Y-E, Lee S-M, Chang C-Y, Chen H, Tsai S-J. 2003. Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients. Neuropsychobiology. 48:72–76.
   PubMed Web of Science ®Google Scholar
• Lim SA, Kang UJ, McGehee DS. 2014. Striatal cholinergic interneuron regulation and circuit effects. Front Synaptic Neurosci. 6:22.
   PubMedGoogle Scholar
• Loonen AJM, Doorschot CH, van Hemert DA, Oostelbos MC, Sijben AE. 2001. The schedule for the assessment of drug-induced movement disorders (SADIMoD): inter-rater reliability and construct validity. Int J Neuropsychopharmacol. 4:347–360.
   PubMed Web of Science ®Google Scholar
• Loonen AJM, Doorschot CH, van Hemert DA, Oostelbos MC, Sijben AE. 2000. The Schedule for the Assessment of Drug-Induced Movement Disorders (SADIMoD): test-retest reliability and concurrent validity. Int J Neuropsychopharm. 3:285–296.
   PubMed Web of Science ®Google Scholar
• Loonen AJM, Ivanova SA. 2013. New insights into the mechanism of drug-induced dyskinesia. CNS Spectr. 18:15–20.
   PubMed Web of Science ®Google Scholar
• Loonen AJM, van Praag HM. 2007. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. J Clin Psychopharmacol. 27:423–430.
   PubMed Web of Science ®Google Scholar
• Luo X, Kranzler HR, Zuo L, Wang S, Blumberg HP, Gelernter J. 2005. CHRM2 gene predisposes to alcohol dependence, drug dependence and affective disorders: results from an extended case-control structured association study. Hum Mol Genet. 14:2421–2434.
   PubMed Web of Science ®Google Scholar
• Luo X, Kranzler HR, Zuo L, Zhang H, Wang S, Gelernter J. 2007. CHRM2 variation predisposes to personality traits of agreeableness and conscientiousness. Hum Mol Genet. 16:1557–1568.
   PubMed Web of Science ®Google Scholar
• McKinzie DL, Bymaster FP. 2012. Muscarinic mechanisms in psychotic disorders. Handb Exp Pharmacol. 213:233–265.
   Google Scholar
• Michel MC, Teitsma CA, 2012. Polymorphisms in human muscarinic receptor subtype genes. Handb Exp Pharmacol. 208:49–59.
   Google Scholar
• Miyauchi M, Kishida I, Suda A, Shiraishi Y, Hattori S, Fujibayashi M, Taguri M, Ishii C, Ishii N, Moritani T, Hirayasu Y. 2016. Association of the cholinergic muscarinic M2 receptor with autonomic nervous system activity in patients with schizophrenia on high-dose antipsychotics. Neuropsychobiology. 74:60–67.
   PubMed Web of Science ®Google Scholar
• Scarr E, Um JY, Cowie TF, Dean B. 2013. Cholinergic muscarinic M4 receptor gene polymorphisms: a potential risk factor and pharmacogenomic marker for schizophrenia. Schizophr Res. 146:279–284.
   PubMed Web of Science ®Google Scholar
• Schooler NR, Kane JM. 1982. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry. 39:486–487.
   PubMed Web of Science ®Google Scholar
• Solmi M, Pigato G, Kane JM, Correll CU. 2018. Clinical risk factors for the development of tardive dyskinesia. J Neurol Sci. 389:21–27.
   PubMed Web of Science ®Google Scholar
• Thongket P, Pleansiri C, Thurakitwannakarn W, Sukhumsirichart W. 2016. Association of cholinergic muscarinic 2 receptor gene polymorphisms with learning aptitude among medical and fine arts students. J Med Assoc Thai. 99:S201–S205.
   PubMedGoogle Scholar
• van Enkhuizen J, Janowsky DS, Olivier B, Minassian A, Perry W, Young JW, Geyer MA. 2015. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. Eur J Pharmacol. 753:114–126.
   PubMed Web of Science ®Google Scholar
• Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen S, Kwon JM, Wu W, Dick DM, Rice J, et al. 2004. Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet. 13:1903–1911.
   PubMed Web of Science ®Google Scholar